Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Melanson SE, Zhao Z, Kumanovics A, Love T, Meng QH, Wu AH, et al. Tolerance for three commonly administered COVID-19 vaccines by healthcare professionals. Front Public Health. 2022;10:975781.

Kubiak JM, Hovan M, Davidson E, Douglass C, Burgos K, Walsh TJ, et al. Comparison between Perianal Swab and Stool Specimens for Detecting Colonization with Extended-Spectrum Beta-Lactamase-Producing and Fluoroquinolone-Resistant Enterobacterales. J Clin Microbiol. 2022;60(7):e0023422.

Kim D, Burkhardt R, Alperstein SA, Gokozan HN, Goyal A, Heymann JJ, et al. Evaluating the role of Z-stack to improve the morphologic evaluation of urine cytology whole slide images for high-grade urothelial carcinoma: Results and review of a pilot study. Cancer Cytopathol. 2022;130(8):630-639.

Aguilar RR, Shen Z-, Tyler JK. A Simple, Improved Method for Scarless Genome Editing of Budding Yeast Using CRISPR-Cas9. Methods Protoc. 2022;5(5).

Nickeleit V, Singh HK, Davis VG, Seshan SV. Classifying Polyomavirus Nephropathy: The "Banff" Initiative. Transpl Int. 2022;35:10299.

Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022;399(10324):541-553.

Rosenthal J, Carelli R, Omar M, Brundage D, Halbert E, Nyman J, et al. Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology. Mol Cancer Res. 2022;20(2):202-206.

Tsui DC, Aisner D, Nijmeh H, Bao L, Menter A, D Camidge R. Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy. Clin Lung Cancer. 2022;23(2):e99-e103.

Nuzzo PV, Adib E, Weise N, Curran C, Stewart T, Freeman D, et al. Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors. Clin Genitourin Cancer. 2022;20(4):301-306.

Xu B, Saliba M, Alzumaili B, Alghamdi M, Lee N, Riaz N, et al. Prognostic impact of extranodal extension (ENE) in surgically managed treatment-naive HPV-positive oropharyngeal squamous cell carcinoma with nodal metastasis. Mod Pathol. 2022;35(11):1578-1586.